Louvain-la-Neuve, Belgium – September 5th, 2024 – The Minafin Group, a leading developer and producer of fine chemicals, today announced the appointment of Olivier Ubrich as CEO of its Health Chemistry division. This division encompasses the company’s “Minakem CDMO” and “Minakem Generics & New Therapies” business units, which focus on the development and manufacturing of pharmaceutical active ingredients. Olivier Ubrich joins Minafin Group Executive Committee.
Olivier Ubrich brings a wealth of international experience and strategic leadership to Minafin. He holds a Process Engineering degree from the École Centrale Marseille and has occupied multiple leadership positions throughout his career. Most recently, he served at Mettler Toledo AutoChem in the United States. Prior to that, he held management roles at BASF, including General Manager of BASF France and Vice President of the global “Specialty Polymers” business. He started his career with Mettler-Toledo in the USA, after completing his doctoral thesis in partnership with Novartis and the École Polytechnique Fédérale de Lausanne in Switzerland.
“Olivier’s expertise as a world-class leader and his deep understanding of the high-value life sciences market are invaluable assets for Minafin,” said Frédéric Gauchet, Chairman of the Minafin Group. “We are confident that he will accelerate our growth in pharmaceutical active ingredients, particularly small molecules and those associated with new therapies. Under his leadership, we will continue to provide our customers with the services they need to deliver efficient and reliable treatments to patients.”
Olivier Ubrich’s key priorities include:
– Strengthening the international presence of the Health Chemistry division, a crucial pillar of Minafin’s growth strategy.
– Leveraging synergies between the Group’s various business units
– Implementing an ambitious growth strategy focused on technology, artificial intelligence, and exceeding customer expectations.
“I am honored to join Minakem, a team renowned for its expertise in chemical synthesis and agility in the field of pharmaceutical active ingredients,” said Olivier Ubrich. “Building on Minakem’s rich history of innovation and strong partnerships, I am committed to expanding our global impact on healthcare. Together, we have the potential to create a better future for our customers and improve lives through our contributions.”
This appointment marks the completion of the Minafin Group’s executive committee renewal, initiated last year. The new team is strategically positioned to navigate the challenges of the coming decade and seize growth opportunities in health and sustainable chemistry. Minafin’s ambition is to solidify its position as a global leader in fine chemicals.
About Minafin Group’s Health Chemistry Division
The Health Chemistry division is a European leader in developing synthesis processes and manufacturing active ingredients for the pharmaceutical industry. Through its Minakem CDMO and Minakem Generics & New Therapies business units, the division offers a comprehensive range of cutting-edge technologies and pharmaceutical services. The company is dedicated to providing customers with a continuous supply of high-quality products and leverages its expertise to develop exclusive manufacturing processes and ensure cGMP-compliant production of pharmaceutical actives. With patient needs at the forefront, the Health Chemistry division prioritizes the strictest health and environmental safety standards for all its manufactured products.
www.minakem.com
About Minafin Group
The Minafin Group is a leader in the development and production of fine chemicals. The company operates through three main business lines: Health Chemistry, Green Chemistry, and Specialty Chemistry. With seven industrial sites across Europe and North America, Minafin caters to a diverse clientele, including pharmaceutical, life sciences, and new technology companies. Additionally, the Group offers solutions for customers seeking to minimize their environmental footprint through sustainable chemistry practices. Minafin provides a comprehensive range of services, including proprietary processes, custom manufacturing, R&D, analytical and regulatory support, and formulations. The company prioritizes significant investment in R&D to deliver value to its customers through innovative and eco-friendly solutions that ensure both competitive advantage and sustainability.
www.minafin.com
Press Contact
Véronique LUTUN –
veronique.lutun@minakem.com
Group Minafin
Rue Fonds Jean Pâques
8 Parc Fleming de Louvain-la-Neuve
B-1435 Mont-Saint-Guibert
+33/750687780